RespireRx Pharmaceuticals Net income (FY, 2018)-2.6 M
RespireRx Pharmaceuticals EBIT (FY, 2018)-2.2 M
RespireRx Pharmaceuticals Cash, 31-Dec-201833.3 K

RespireRx Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

48.3k

R&D expense

826.7k

General and administrative expense

1.9m

Operating expense total

7.4m5.3m8.5m4.2m2.2m

EBIT

(7.3m)(5.2m)(8.5m)(4.2m)(2.2m)

EBIT margin, %

(15177%)

Interest income

92.09.08.0

Net Income

(7.6m)(6.0m)(9.2m)(4.3m)(2.6m)

Quarterly

USDQ3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

74.5k

R&D expense

191.9k83.9k64.1k80.4k171.8k145.4k

General and administrative expense

389.4k759.3k438.6k

Operating expense total

1.7m843.2k64.1k80.4k171.8k670.7k584.0k2.4m2.3m1.5m593.1k506.2k586.8k

EBIT

(1.7m)(843.2k)(2.4m)(287.7k)(964.7k)(596.2k)(1.1m)(2.0m)(2.4m)(2.3m)(2.2m)(1.4m)(1.5m)(593.1k)(506.2k)(586.8k)

EBIT margin, %

(800%)

Interest expense

1.2k

Net Income

(1.8m)(837.4k)(1.4m)62.4k(643.1k)(728.0k)(2.0m)(2.3m)(2.7m)(2.7m)(2.4m)(1.5m)(1.6m)(618.5k)(746.7k)(635.4k)

RespireRx Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2015FY, 2016FY, 2017FY, 2018

Cash

152.2k53.2k92.0k84.9k33.3k

Accounts Receivable

116.0m

Inventories

4.6m

Current Assets

169.2k85.8k195.7k176.7k121.1k

Total Assets

198.7k145.8k233.8k194.8k124.2k

Accounts Payable

1.5m2.6m

Current Liabilities

3.2m3.0m5.7m4.6m5.9m

Additional Paid-in Capital

125.2m144.6m152.0m157.4m158.6m

Retained Earnings

(128.3m)(148.3m)(157.5m)(161.8m)(164.4m)

Total Equity

(3.0m)(2.9m)(5.5m)(4.4m)(5.7m)

Financial Leverage

-0.1 x-0.1 x0 x0 x0 x

Quarterly

USDQ3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

224.3k7.6k311.9k172.7k32.9k154.2k53.2k404.5k6.1k347.3k39.6k220.9k30.8k52.2k266.0874.0

Current Assets

234.9k105.7k365.2k239.7k86.1k318.6k154.9k448.0k82.6k528.7k157.0k378.6k163.3k161.5k149.8k132.4k

Total Assets

3.7m135.3k441.2k311.8k166.2k395.1k226.0k513.6k137.2k577.8k200.7k411.3k190.7k183.6k164.2k143.0k

Accounts Payable

1.3m1.7m1.9m1.5m1.6m

Current Liabilities

2.8m4.0m2.9m2.5m2.3m3.0m2.8m2.6m3.9m4.3m5.0m6.3m6.5m6.9m5.1m5.2m

Additional Paid-in Capital

125.2m125.2m128.7m137.6m138.2m139.3m141.0m143.7m146.4m149.3m151.2m153.0m154.2m154.4m157.5m158.1m

Retained Earnings

(124.5m)(129.2m)(132.1m)(140.9m)(141.6m)(143.0m)(144.3m)(146.6m)(151.0m)(153.7m)(156.1m)(159.0m)(160.6m)(161.2m)(162.5m)(163.2m)

Total Equity

881.3k(3.8m)(2.5m)(2.2m)(2.1m)(2.6m)(2.1m)(3.7m)(4.8m)(5.9m)(6.3m)(5.1m)

Financial Leverage

4.2 x0 x-0.2 x-0.1 x-0.1 x-0.2 x-0.2 x-0.2 x0 x-0.1 x0 x0 x

RespireRx Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(7.6m)(6.0m)(9.2m)(4.3m)(2.6m)

Depreciation and Amortization

26.4k7.1k7.0k5.2k

Accounts Payable

871.9k490.4k1.2m476.4k703.7k

Cash From Operating Activities

(1.9m)(1.3m)(1.3m)(697.0k)(427.4k)

Cash From Investing Activities

24.7k(2.5k)

Cash From Financing Activities

378.4k1.2m1.4m689.9k375.8k

Interest Paid

6.9k1.1k2.6k3.3k

Quarterly

USDQ3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(3.7m)(837.4k)(1.4m)62.4k(643.1k)(728.0k)(2.0m)(2.3m)(2.7m)(5.4m)(2.4m)(1.5m)(3.1m)(3.7m)(746.7k)(1.4m)

Depreciation and Amortization

20.1k1.9k3.6k1.7k3.5k3.3k4.9k

Accounts Payable

666.8k195.1k1.9m1.5m1.6m327.4k519.8k334.9k643.7k277.0k463.5k141.4k336.5k

Cash From Operating Activities

(1.8m)(144.6k)(200.4k)(322.7k)(343.3k)(867.9k)(456.4k)(495.8k)(140.0k)(184.0k)

Cash From Investing Activities

24.7k(2.5k)(2.5k)

Cash From Financing Activities

378.4k194.3k215.6k296.2k1.2m395.2k456.0k55.4k100.0k

Interest Paid

750.01.2k8.0562.01.3k2.1k190.0682.0

RespireRx Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase II Trials Products

4

Preclinical Phase Products

1